Kamila Silva, Anna Julia Ribeiro, Isadora Gandra, Carlos Rezende, Lucas Lopes, Carolina Couto, Verônica Freire, Isabelle Barcelos, Sabrina Pereira, Sandra Xavier, Mariana Campos-da-Paz, Rodolfo Giunchetti, Miguel Chávez-Fumagalli, Ana Alice Gonçalves, Eduardo Coelho and Alexsandro Galdino* Pages 1 - 18 ( 18 )
Improving the diagnostic technology used to detect tegumentary leishmaniasis (TL) is essential in view of it being a widespread, often neglected tropical disease with cases reported from the southern United States to northern Argentina. Recombinant proteins, recombinant multiepitope proteins, and synthetic peptides have been extensively researched and used in disease diagnosis. One of the benefits of applying these antigens is a measurable increase in sensitivity and specificity, which improves test accuracy. The present review aims to describe the antigens and their diagnostic effectiveness. With that in mind, a bibliographic survey was conducted on the PudMed platform using the search terms “tegumentary leishmaniasis” AND “diagno”, revealing that recombinant proteins have been described and evaluated for their value in TL diagnosis since the 1990s. However, there was a spike in the number of publications using all of the antigens between 2013 and 2022, confirming an expansion in research efforts to improve diagnosis. Moreover, all of the studies involving different antigens had promising results, including improved sensitivity and specificity. These data recognize the importance of doing research with new technologies focused on developing quick, more effective diagnostic kits as early diagnosis facilitates treatment.
Tegumentary leishmaniasis, diagnosis, recombinant protein, recombinant multiepitope protein, syntheticpeptide.